NeuroBo Pharmaceuticals (NRBO) News Today $4.15 +0.06 (+1.47%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 11, 2024 | prnewswire.comNeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in JulyJune 30, 2024 | 247wallst.comHuge Insider Buying at a Warren Buffett Pick and 5 Other StocksJune 26, 2024 | prnewswire.comNeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityJune 26, 2024 | insidertrades.comNeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Major Shareholder St Co. Ltd Dong-A Acquires 2,544,530 SharesJune 25, 2024 | prnewswire.comNeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 24, 2024 | prnewswire.comNeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 22, 2024 | prnewswire.comNeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical ModelsMay 28, 2024 | finance.yahoo.comNRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024May 28, 2024 | finance.yahoo.comNRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024May 22, 2024 | markets.businessinsider.comNeuroBo Pharma Reveals Positive Pre-clinical Data For DA -1241 In Combination In Liver FibrosisMay 22, 2024 | msn.comNeuroBo says DA-1241, Wegovy combo shows potential in treating MASHMay 22, 2024 | msn.comNeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis SuccessMay 22, 2024 | prnewswire.comNeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, AloneMay 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for NeuroBo Pharmaceuticals on Promising Obesity and MASH Drug DevelopmentsMay 9, 2024 | msn.comMaxim Group Initiates Coverage of NeuroBo Pharmaceuticals (NRBO) with Buy RecommendationMay 9, 2024 | investorplace.comNRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024May 9, 2024 | prnewswire.comNeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 30, 2024 | prnewswire.comNeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneApril 23, 2024 | finance.yahoo.comNRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…April 17, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 17, 2024 | prnewswire.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 5, 2024 | morningstar.comNeuroBo Pharmaceuticals Inc NRBOApril 1, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHMarch 28, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | prnewswire.comNeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | markets.businessinsider.comNeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%March 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHMarch 4, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerMarch 4, 2024 | msn.comNeuroBo Pharmaceuticals appoints Marshall Woodworth as CFOMarch 4, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFOMarch 4, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerFebruary 29, 2024 | markets.businessinsider.comNeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock GainsFebruary 29, 2024 | prnewswire.comNeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityFebruary 12, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor ConferenceFebruary 6, 2024 | finance.yahoo.comNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…February 2, 2024 | msn.comNeuroBo’s DA-1726 Obesity Therapy Gets FDA IND ApprovalFebruary 1, 2024 | msn.comWhy Obesity-Drug Maker NeuroBo Stock Is Trading HigherFebruary 1, 2024 | markets.businessinsider.comNeuroBo Pharma'a IND Application For DA-1726 Gets FDA ClearanceFebruary 1, 2024 | markets.businessinsider.comNeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726February 1, 2024 | msn.comNeuroBo to begin Phase 1 testing of potential Wegovy rivalFebruary 1, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityJanuary 30, 2024 | investing.comNeurobo Pharmaceuticals Inc (NRBO)January 18, 2024 | markets.businessinsider.comNeuroBo Announces Positive Pre-Clinical Safety Data Of DA-1241 In Combination With SitagliptinJanuary 18, 2024 | finance.yahoo.comNRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…January 18, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHJanuary 9, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price RequirementJanuary 9, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price RequirementJanuary 2, 2024 | finance.yahoo.comNeuroBo to Participate in Industry and Investor Conferences in JanuaryDecember 29, 2023 | msn.comWhat's Going On With Clinical-Stage Biotech Firm NeuroBo Shares Today?December 28, 2023 | benzinga.comNeuroBo Pharmaceuticals Stock (NASDAQ:NRBO), Short Interest Report Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address J.P. Morgan’s DIRE Warning (Ad)When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell." Click here to see why Wall Street is in PANIC mode >>> NRBO Media Mentions By Week NRBO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRBO News Sentiment▼1.430.62▲Average Medical News Sentiment NRBO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRBO Articles This Week▼21▲NRBO Articles Average Week Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BeyondSpring News Verastem News Eton Pharmaceuticals News Clearside Biomedical News Kronos Bio News Genelux News AEON Biopharma News Milestone Pharmaceuticals News IO Biotech News PMV Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRBO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.